The release of a Chantix study last week that linked the drug to numerous side effects has prompted the Food & Drug Administration (FDA) to initiate another safety review of the drug. The review will mark the second such investigation for Chantix, which is already being scrutinized because of its association with psychiatric side effects, including suicide and depression.
Chantix is a popular anti-smoking drug made by Pfizer, Inc. It was approved in 2006, and was the first nicotine receptor partial agonist – meaning it blocks nicotine receptors in the brain – on the market. Last Tuesday, the Institute for Safe Medication Practices issued a report detailing Chantix adverse event repots to the FDA. The report specifically cited 224 reports of potential heart-rhythm disturbances, 372 reports of possible movement disorders and 544 reports of likely glycemic problems, including diabetes. There were also reports of traffic accidents and falls linked to Chantix. As a result of the Institute’s report, the Federal Aviation Administration banned Chantix use by pilots and air traffic controllers. Earlier this week, the Federal Motor Carrier Safety Administration said that “… it appears that medical examiners should not certify a driver taking Chantix because the medication may adversely affect the driver’s ability to safely operate a commercial motor vehicle.” (more…)

